featured
Combining Checkpoint Inhibitors and VEGF Inhibitors for First-Line RCC: Early Data and Indications—A West Cancer Center Perspective
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles: